Large scale non-invasive screening of EGFR mutations in advanced NSCLC patients: Identify platform experience Clara Mayo de las Casas, Núria Jordana Ariza, Mónica Garzón Ibañez, Ariadna Balada Bel, Jordi Bertrán-Alamillo, Ana Pérez Rosado, Santiago Viteri Ramirez, Daniela Morales Espinosa, Juan Carlos Monasterio, Niki Karachaliou, Miguel Ángel Molina Vila, Rafael Rosell.
Poster #3964
BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group) Maria Gonzalez Cao, Jose Luis Manzano, Virtudes Soriano, Teresa Puertolas, Ainara Soria, Clara Mayo, Margarita Magem, Miguel Angel Molina, Clara Montagut, Eva Muñoz, Delvys Rodriguez, Eva Perez, Almudena Garcia, Javier Cortes, Nuria Jordana, Jordi Rodon, Niki Karachaliou, Rafael Rosell.
Poster #468
PB1, a DDR2 inhibitor with antitumor activity in preclinical models of squamous cell carcinoma and KRAS mutated adenocarcinoma of the lung Silvia García-Roman, Miguel Angel Molina, Jose Iñaki Borrell, Raimon Puig de la Bellacasa, Daniela Morales, Jordi Bertrán, Ana Gimenez-Capitán, Niki Karachaliou, Rafael Rosell.
Poster #4802
Inhibition of epidermal growth factor receptor pathway by epidermal growth factor antibodies in non-small-cell lung cancer Jordi Codony-Servat, Miguel Angel Molina-Vila, Jordi Bertran-Alamillo, Eric d’Hondt, Rafael Rosell.
Poster #2368
S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation Jordi Bertran-Alamillo, Miguel Angel Molina-Vila, Cristina Teixidó, Carles Codony-Servat, Jordi Codony-Servat, Rafael Rosell.
Poster #336